$BLCO reported third-quarter revenue of $1.375 billion, up 7% year over year (+8% at constant currency). GAAP net income swung from a loss of $28 million in the year-ago quarter to a profit of $32 million. Adjusted EBITDA was $325 million, with a 23.6% margin, up 460 basis points from a year ago. The company raised its full-year guidance for the third time, lifting the midpoint of its revenue outlook to about $5.5 billion and its adjusted EBITDA outlook to $1.09–$1.14 billion. Its shares surged about 16% that day.
Fundamentally, all three major segments grew: dry-eye drug MIEBO revenue rose 42%, consumer brand LUMIFY grew 35%, and premium intraocular lenses rose about 70%. Net leverage also fell from 5.7x to 4.1x.
But on closer inspection, nearly all the report’s highlights were in margins, not revenue: the midpoint of full-year EBITDA guidance rose by $65 million, while the revenue midpoint increased by just $10 million. Growth quality still hinges on cost cutting and product mix. There’s also a crack in the financial picture: quarterly interest expense was $95 million, nearly two-thirds of operating income of $155 million, and the interim CEO handover remains unresolved. The market’s 16% cheer seems more like a bet on “marginal improvement” than confirmation of a “trend reversal.”
In a slow-growth field like eye care, how far can a rebound driven by margins go?
Fundamentally, all three major segments grew: dry-eye drug MIEBO revenue rose 42%, consumer brand LUMIFY grew 35%, and premium intraocular lenses rose about 70%. Net leverage also fell from 5.7x to 4.1x.
But on closer inspection, nearly all the report’s highlights were in margins, not revenue: the midpoint of full-year EBITDA guidance rose by $65 million, while the revenue midpoint increased by just $10 million. Growth quality still hinges on cost cutting and product mix. There’s also a crack in the financial picture: quarterly interest expense was $95 million, nearly two-thirds of operating income of $155 million, and the interim CEO handover remains unresolved. The market’s 16% cheer seems more like a bet on “marginal improvement” than confirmation of a “trend reversal.”
In a slow-growth field like eye care, how far can a rebound driven by margins go?